Sarepta Therapeutics is under increased scrutiny following the deaths of three patients linked to its gene therapies for muscular dystrophy. Two teenagers died after treatment with Elevidys, the gene therapy for Duchenne muscular dystrophy, leading the FDA to request a halt to its shipment. A third fatality occurred in a clinical trial for limb-girdle muscular dystrophy involving another Sarepta gene therapy, raising broader safety concerns over liver toxicity. Sarepta's CEO defended the company's transparency amid criticism surrounding the handling of these incidents. The FDA is evaluating whether Elevidys should remain on the market, and Sarepta is revising its development pipeline and workforce.